Pityriasis lichenoides et varioliformis acuta  is a disease of the immune system. It is the more severe version of pityriasis lichenoides chronica. The disease is characterized by rashes and small lesions on the skin. The disease is more common in males and usually occurs in young adulthood, although it has been seen in every age group and every race. It is possible for the disease to go into remission for short periods of time or forever. Causes
There is no known cause of this disease; There is some evidence associating it with Parvovirus B19. Diagnosis
It is commonly misdiagnosed as chickenpox or rosacea, or misidentified as a form of Staph infection. The most accurate way to diagnose it is by biopsy. This disease has not been known to be life-threatening. Treatment
It is not contagious and currently there is no cure for the disease, although the lesions can be treated with phototherapy as well as antibiotics, including erythromycin, azithromycin and tetracycline. Treatment often involves multiple therapies that address the immune system and bacterial, viral, or dermatological causes. Eponym
Pityriasis lichenoides et varioliformis acuta is also known as Mucha–Habermann disease. It is named for Rudolf Habermann (1884–1941), a German dermatologist, and Viktor Mucha, an Austrian dermatologist. See also
Cutaneous T-cell lymphoma
Pityriasis lichenoides
Parapsoriasis
List of cutaneous conditions

References
External links
DermNet scaly/pityriasis-lichenoides
This increased dopamine concentration is theorized to act on dopamine D1 receptors to relieve depressive symptoms (in dysthymia) and the negative symptoms of schizophrenia.It was introduced by Sanofi-Aventis in the 1990s. Its patent expired by 2008, and generic formulations became available. It is marketed in all English-speaking countries except for Canada. A New York City based company, LB Pharmaceuticals, has announced the ongoing development of LB-102, also known as N-methyl amisulpride, an antipsychotic specifically targeting the United States. A poster presentation at European Neuropsychopharmacology seems to suggest that this version of amisulpride, known as LB-102 displays the same binding to D2, D3 and 5HT7 that amisulpride does. Medical uses
Schizophrenia
Although according to other studies it appears to have comparable efficacy to olanzapine in the treatment of schizophrenia, amisulpride augmentation, similarly to sulpiride augmentation, has been considered a viable treatment option (although this is based on low-quality evidence) in clozapine-resistant cases of schizophrenia. Another recent study concluded that amisulpride is an appropriate first-line treatment for the management of acute psychosis. Postoperative nausea and vomiting
Amisulpride is indicated for use in the United States in adults for the prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class; and to treat PONV in those who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis. Contraindications
Amisulprides use is contraindicated in the following disease states
Pheochromocytoma
Concomitant prolactin-dependent tumours e.g. prolactinoma, breast cancer
Movement disorders (e.g.